Sobre 5 señales de compra con un rendimiento T+90 consolidado. Base de rendimiento: cierre del día siguiente a la publicación.
Historial de señales
Explore the detailed record of transactions filed by Tang Kevin. Director active across 4 companies, notably Singular Genomics Systems, Inc.. Cumulatively, 41 reports have been recorded. Split: 40 buys · 0 sell. Total volume traded: €34m. Activity tracked since 16 September 2024. The latest transaction was disclosed on 17 July 2026 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Tang Kevin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
TANG KEVIN has 36 filings in total. In the sampled recent filings from 2024-09-18 to 2026-07-16, all transactions are acquisitions, with total purchases of EUR 33482416 and no sales. He is associated with Aurinia Pharmaceuticals Inc. as Chief Executive Officer, with Boundless Bio, Inc. as a 10% Owner, with Fulcrum Therapeutics, Inc. as a 10% Owner, and with Singular Genomics Systems, Inc. with no role listed.